Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-EDV-D682 + EDV-GC in advanced EGFR-expressing solid tumors
ACTRN12625000203459Phase 2Recruiting
- Sponsor
- EnGeneIC
- Start
- Apr 2025
- Modality
- Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EGFR(V)-EDV-PNU and EDV-GC in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), mesothelioma and 8 more, sponsored by EnGeneIC. Primary endpoints: Safety and tolerability of E-EDV-D682/GC, Overall survival and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
EGFR(V)-EDV-PNUEDV-GC
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)mesotheliomabladder cancerkidney cancer
Beyond the preview
Go deeper on ACTRN12625000203459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000203459.